Pulairun (Afatinib) 40mg Tablets | Hansoh China Generic | GLT

Generic Information: Pulairun (Afatinib) — Hansoh, China

Pulairun is a domestic Chinese generic of afatinib produced by Jiangsu Hansoh Pharmaceutical Group Co., Ltd., the company that won China's first generic approval for afatinib and passed the national consistency evaluation. Supplied as 40 mg film-coated tablets in a convenient 30-tablet pack, Pulairun brings the second-generation, irreversible EGFR inhibitor to patients in a larger monthly format at a substantially lower price than the originator, making long-term EGFR-targeted therapy far more accessible across China.

What Is Pulairun (Afatinib) Used For?

Pulairun is used to treat locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations, including exon 19 deletions, the L858R substitution, and uncommon mutations like G719X, L861Q and S768I. It is a first-line therapy for EGFR-mutant NSCLC and is also used in metastatic squamous NSCLC after progression on platinum-based chemotherapy.

How Does Pulairun (Afatinib) Work?

Pulairun's active ingredient afatinib is an irreversible pan-ErbB tyrosine kinase inhibitor that covalently binds EGFR, HER2 and ErbB4, permanently disabling the signaling that EGFR-mutant cancer cells need to grow and survive. As China's first afatinib generic to pass consistency evaluation, Pulairun is bioequivalent to the originator and delivers the same durable disease control.

Indications

Pulairun is indicated for adults with locally advanced or metastatic non-small cell lung cancer whose tumors have non-resistant EGFR mutations, and for metastatic squamous NSCLC progressing after platinum-based chemotherapy. EGFR mutation testing is required before initiating therapy.

Dosage

The recommended dose is 40 mg once daily, taken at least one hour before or two hours after a meal. The 30-tablet pack provides approximately one month of therapy. A 30 mg dose may be used for severe renal impairment or to manage tolerability, under oncologist supervision.

Side Effects

Common side effects of Pulairun include diarrhea, acneiform rash, stomatitis, paronychia, dry skin and decreased appetite, consistent with the afatinib class. Serious events such as interstitial lung disease, hepatotoxicity and severe skin reactions are rare but require prompt medical attention. Proactive management of diarrhea and skin symptoms is recommended.

Storage

Store Pulairun in a cool, dry place away from sunlight and moisture, in its original packaging. Keep out of reach of children and swallow tablets whole with water.

Why Choose the GLT?

Pulairun through GLT provides China's first-approved afatinib generic in a practical 30-tablet monthly pack, at a cost that dramatically improves affordability for patients requiring ongoing EGFR-targeted therapy. As a Hong Kong-licensed supplier, we source genuine stock and provide the documentation needed for confident purchasing. For those seeking a proven, consistency-evaluated domestic generic, Pulairun is an excellent choice.

How to Order Pulairun (Afatinib)

To order, contact us on WhatsApp at +86 15234153837 or by email at [email protected]. Share your quantity and destination, and we will confirm availability, pricing and delivery.

FAQ

Who makes Pulairun? Pulairun is produced by Jiangsu Hansoh Pharmaceutical Group, which obtained China's first generic approval for afatinib and passed the consistency evaluation.

Is Pulairun equivalent to the originator? Yes, Pulairun passed the national consistency evaluation, confirming bioequivalence to the originator afatinib.

What strength and pack size are available? This listing covers the 40 mg, 30-tablet pack, which is about one month of once-daily therapy.

Do I need a prescription? Yes, afatinib is a prescription oncology medicine used under physician supervision.